B cell deficiency is a common condition that can result either from immunosuppressant drugs used to treat autoimmune disease or certain cancers—such as rituximab (RTX)—or from natural immune deficiency. These patients ...
Dec 18, 2023
0
44
In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic ...
Apr 27, 2020
0
10
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...
Dec 3, 2021
0
9
Cancer therapies that target specific genetic abnormalities in tumors have revolutionized treatment possibilities over the past two decades. While quality of life and survival are improved with targeted therapies, relapse ...
Jul 13, 2023
0
18
A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.
Aug 14, 2023
0
13
With the new year comes another round of prescription drug price hikes, CBS News reported Tuesday.
Jan 7, 2021
0
2
A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.
Feb 16, 2021
0
3
New results from the FinnGen research consortium demonstrate the undeniable benefits of Finnish health research environment for genomic research. Among the wealth of novel genetic discoveries are previously unknown genetic ...
Jan 18, 2023
0
27
An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.
Jun 4, 2012
0
0
(HealthDay)—For patients with advanced, chemotherapy-pretreated, immune checkpoint inhibitor-naive squamous (Sq) non-small cell lung cancer (NSCLC), ipilimumab added to nivolumab does not improve outcomes versus nivolumab ...
Jul 16, 2021
0
1
